VIAVI Invests in PCIe 7.0 Test Platform Amidst Overvaluation and Leverage Risks

What happened

VIAVI Solutions announced an investment in a new PCIe 7.0 protocol analysis testing platform, showcasing its commitment to supporting next-generation data center speeds and reinforcing its position in the AI/network test market. This announcement comes as the company trades at a premium valuation (~304x trailing P/E) with significant leverage from the recent Spirent acquisition, leaving little margin of safety. While the PCIe 7.0 investment strengthens the long-term growth narrative, it does not address near-term risks such as customer concentration, potential AI capex digestion, and integration execution. The DeepValue Master Report rates VIAV as a STRONG SELL, citing that even under the base case scenario, the current price embeds overly optimistic assumptions. Therefore, the news provides a positive technical update but does not materially change the unfavorable risk/reward calculus.

Implication

The PCIe 7.0 testing platform investment underscores VIAVI's efforts to stay at the forefront of data center test technologies, which could support revenue growth in the medium term. However, this positive development does not alter the fundamental overvaluation: the stock trades at over 300x trailing EPS and 37x EV/EBITDA, with net debt/EBITDA at 2.05x and interest coverage below 3x. The DeepValue report highlights that any disappointment in AI spending, Spirent integration, or margin compression could lead to severe multiple compression from current elevated levels. Investors should view this news as a confirmation of the AI infrastructure theme but recognize that the stock already prices in a high-probability bull case. Until the company demonstrates sustained revenue growth above $1.35B and non-GAAP margins above 16% while reducing leverage, the risk of capital impairment remains elevated, and new capital should be deployed elsewhere.

Thesis delta

The PCIe 7.0 investment supports the long-term AI narrative but does not alter the near-term overvaluation and balance sheet risk. The thesis remains that VIAV is a STRONG SELL at current prices, as the positive product news is already reflected in the valuation and does not mitigate the downside risks from leverage and execution. No shift in the investment thesis is warranted; the stock's risk/reward remains unfavorable.